MATREYA LLC
Lipids and Biochemicals
2178 High Tech Road, State College, PA 16803
Tel. 814-355-1030 Fax 814-355-1031 www.matreya.com

PRODUCT DATA SHEET

L-*threo*-Dihydrosphingosine (Safingol)

Catalog number: 1807; 1807-025
Common Name: L-*threo*-Sphinganine, C18 chain
Source: synthetic
Solubility: chloroform, methanol, ethanol, DMSO
CAS number: 15639-50-6

Molecular Formula: $C_{18}H_{39}NO_2$
Molecular Weight: 301
Storage: -20°C
Purity: TLC: >98%, GC: >99%
TLC System: chloroform/methanol/DI water/ ammonium hydroxide (70:20:1:1 by vol.)
Appearance: solid



Application Notes:

Safingol is a fully saturated, nonnatural analogue of sphingosine that has anticancer properties and is being investigated for its potential as an antitumor therapy. It has been shown to inhibit both protein kinase C (PKC) and sphingosine kinase. Safingol competitively interacts at the regulatory phorbol-binding domain of PKC, which is a kinase involved in tumorigenesis. Safingol has been shown to potentiate the effect of doxorubicin (DOX) in tumor-bearing animals.[1] It has been reported that safingol is able to increase the activity of DOX and other chemotherapeutic agents, including mitomycin C, by generating the pro-apoptotic second messenger ceramide, even in tumor cell lines that were resistant to chemotherapy due to mutations.[2] However, a study has recently claimed that safingol induces cell death of an exclusively autophagic character and lacking any of the hallmarks of apoptosis.[3] Safingol inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils and phorbol ester-induced edema and neutrophil influx. Safingol also demonstrates anti-inflammatory activity. Safingol, like the natural sphinganine, is used as a biosynthetic precursor for all complex sphingolipids although the metabolism of the natural and the nonnatural compounds are different.[4]

Selected References:

1. Darges, et al. "Inhibition of leukotriene B4 (LTB4) in human neutrophils by L-threo-dihydrosphingosine" *Adv. Exp. Med. Biol,* Vol. 400A pp. 387-392, *1997*
2. G. Schwartz, et al. "A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin" *Clin. Cancer Res,* Vol. 3 pp. 537-543, *1997*
3. J. Coward et al. "Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway" *Autophagy* Vol. 5(2) pp.184-193, *2009*
4. M. Dragusin et al. **"**Metabolism of the unnatural anticancer lipid safingol,L-*threo*-dihydrosphingosine, in cultured cells" Vol. 44 pp. 1772, *2003*